BUZZ-Shire: relief over FDA drug approval
** Shire (Xetra: S7E.DE - news) tops FTSE 100, up at its highest levels in more than 3 mths after the US FDA approves NPS Pharmaceuticals' drug Natpara - validating Shire's recent takeover of NPS
** Panmure Gordon hikes its TP for Shire to 5,500p vs 5,000p
** Broker - rated at five stars for recommendation accuracy on Shire, according to StarMine - calls deal a strong therapeutic & strategic fit & expects NPS nascent product portfolio to benefit from Shire's broader channel to market
** Analysts at Jefferies reckon the commercial opportunity for the drug should be significant
** Natpara designed to treat hypoparathyroidism, a condition in which the body's parathyroid gland does not secrete enough parathyroid hormone (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)